THE SOME ECONOMIC ASPECTS OF PRODUCTION OF PHARMACEUTICAL SUBSTANCE HYDROXYETHYL STARCH IN SMALL INDUSTRIAL SCALE

This article describes economic aspects of the technology of drug substance hydroxyethyl starch (HES) 130/0.4 production in small industrial scale. This substance is used as plasma substitute and has several advantages over other analogs (infusion solutions based on gelatin, dextran, albumin, blood plasma etc.) such as low cost, guaranteed lack of viruses, a small number of adverse effects and health complications. Developing the technology for producing this substance is of current interest, because only foreign HES and infusion solutions from foreign manufacturers are present in the Russian market today. As of 2016, the total market volume of HES-based infusion solutions was about 157 million rubles. So, its production is quite promising. The authors of this article calculated the cost of organizing this substance production in small scale (500 kg per year). The cost of equipment, reagents and organizational procedures for the first and subsequent years was calculated. As expected, the source of funding is a grant of the Foundation for Assistance to Small Innovative Enterprises, as well as private investors interested in implementing this project. The project generates a net present value of 644470 rubles, and the investments pay-back period will be a little more than one year. In addition to repayment of resources, the project will allow developing a technology for larger scales. This will enable facilitating the organization of industrial scale pharmaceutical manufacturing.

drugs, drug substance, pharmacy, hydroxyethyl starch, infusion solutions, import substitution, economical aspects

1. Pharmaceutical market in Russia 2016 [Electronic resource]. URL: http://www.dsm.ru/docs/analytics/Annual_Report_2016_rus.pdf. (Date accessed 01.11.2017). (in Russ.)

2. Romanova S. Pharmaceutical substances: Prerequisites and prospects for production development // Remedium. 2015. P. 8–14. (in Russ.)

3. Vasilenko I.A., Tolmachev S.A. Prospects of creating of the pharmaceutical ingredients production in Russia // Razrabotka i registraziy lekarstvennih sredstv (Drug Development and Registration). 2015. № 10. P. 190–196. (in Russ.)

4. Shulkin A.V., Popova N.M., Chernykh I.V. The original and generic drugs: Current state of the problem // Nauka Molodykh – Eruditio juvenium. 2016. № 2. P. 30–35. (in Russ.)

5. Kedik S.A., Panov A.V., Eremin D.V., Suslov V.V., Sakaeva I.V., Kochkina Yu.V. Synthesis and molecular-weight characteristics of N-vinylpyrrolidone and 2-methyl-5-vinylpyridine copolymers // Pharmaceutical Chemistry Journal. 2012. V. 46. № 8. P. 478–481.

6. Avrutskaya S.G., Vorobyova T.Yu. Development of Russian pharmaceutical industry: Realization of Pharma-2020 strategy // Uspehi v khimii i himicheskoi tehnologii (Adnvances in Chemistry and Chemical Technology). 2013. V. 27. № 8. P. 23–28. (in Russ.)

7. Mikhailov V.G., Koryakov A.G., Mikhailov G.S. Ecological risk management in coal mining and processing // J. Mining Sci. 2015. V. 51. №. 5. P. 930–936.

8. Shinkevich A.I., Lubnina A.A., Koryakov A.G., Mikhailov V.G., Vodolazhskaya E.L. Economic aspects of risk management of stakeholders activities // Int. Rev. Management and Marketing. 2016. V. 6. № 2. P. 328–332.

9. Koryakov A.G. The stages and content of the program of states support for enterprises sustainable development // Biznes v zakone. Ekonomiko-uridicheskii zhurnal (Business in law). 2012. № 4. P. 115–117. (in Russ.)

10. Koryakov A.G. Mechanism of potential assessment of sustainable development of enterprises of chemical industry: structure and implementation phases // Statistika i ekonomika (Statistics and Economics). 2012. № 5. P. 70–73. (in Russ.)

11. Koryakov A.G. The science approaches for performing of prepositions of sustainable development for russian manufactories’ branches of economy // Transportnoe delo Rossii (Transport Business in Russia). 2012. V. 100. № 3. P. 121–124. (in Russ.)

12. Koryakov A.G. The social, ecological and economic components of forming sustainable development principles for enterprises // Mikroekonomika (Microeconomics). 2012. № 2. P. 88–92. (in Russ.)

13. Butrov A.V., Borisov A.Yu., Galenko S.V. Hydroxyethyl starch solutions in infusion therapy of acute blood loss // Russian Medical Journal. 2006. № 28. P. 2019–2023. (in Russ.)

14. Egorov O.О., Peycheva O.I., Li А.V., Kupershmidt V.R., Nalapko Yu.I. Hydroxyethyl starches of different generations: from chemistry to clinic // Ukrainian Journal of Extremal Medicine by G.O. Mozhaev. 2012. V.13. № 1. P. 11–14. (in Russ.)

15. Raiman M., Mitchell C.G., Biccard B.M., Rodseth R.N. Comparison of hydroxyethyl starch colloids with crystalloids for surgical patients: A systematic review and meta-analysis // Eur. J. Anaesthesiology. 2016. V. 33. № 1. P. 42–48.

16. Jungheinrich C. The starch family: are they all equal? Pharmacokinetics and pharmacodynamics of hydroxyethyl starches // Transfus. Alternat. in Transfus. Med. 2007. V. 9. P. 152–163.

17. Mutter T.C., Ruth C.A., Dart A.B. Hydroxyethyl starch (HES) versus other fluid therapies: effects on kidney function // Cochrane Database of Systematic Reviews. 2013. № 7. Art. No. CD007594.

18. Standl T., Burmeister M.A.,Schroeder F.,Currlin E.,Schulte Esch J.,Freitag M.,Schulte Esch J. Hydroxyethyl Starch (HES) 130/0.4 Provides Larger and Faster Increases in Tissue Oxygen Tension in Comparison with Prehemodilution Values than HES 70/0.5 or HES 200/0.5 in Volunteers Undergoing Acute Normovolemic Hemodilution // Anesthesia & Analgesia. 2003. V. 96. № 4. P. 936–943.

19. Panov A.V., Korotaev G.K., Kyryanov N.A., Dolotov S.M., Grineva L.P., Kotova Y.A. Pharmaceutical substance, its production method and medication : patent 2451691 Russian Federation. 2010124420/05; filed 17.06.2010; publ. 27.05.2012. Bull. № 15. (in Russ.).